Funding for this research was provided by:
National Institute of Mental Health,United States (MH101874, MH101874)
Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis
Received: 31 March 2022
Accepted: 14 July 2022
First Online: 20 July 2022
: CFZ serves on the Scientific Advisory Board of Sage Therapeutics and has equity in Sage Therapeutics. Sage Therapeutics did not fund this research. Other authors have no conflicts to declare.